Stocktoria
Allarity Therapeutics, Inc. ALLR
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2021-12-21
Allarity Therapeutics, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $320,000 | $0 | — | — | — |
| Gross profit | — | — | — | -$2.3M | — |
| R&D expense | $6.6M | $6.1M | $7.1M | $6.9M | $14.2M |
| Operating income | -$12.6M | -$27.2M | -$17.1M | -$34.5M | -$26.6M |
| Interest expense | — | — | $498,000 | $223,000 | — |
| Income tax | $0 | -$381,000 | $83,000 | -$1.5M | $133,000 |
| Net income | -$11.2M | -$24.5M | -$11.9M | -$16.1M | -$26.6M |
| EPS (diluted) | — | — | $-10.26 | $-3093.42 | $-4.19 |
| Operating cash flow | -$14.8M | -$17.4M | -$12.7M | -$16.8M | -$14.9M |
| Free cash flow | -$14.8M | -$17.6M | -$12.7M | -$16.8M | — |
| Cash & equivalents | $14.7M | $19.5M | $166,000 | $2.0M | — |
| Total assets | $18.3M | $22.6M | $11.9M | $14.5M | $49.6M |
| Total liabilities | $8.4M | $10.8M | $14.6M | $12.7M | $30.8M |
| Shareholders' equity | $9.8M | $11.8M | -$2.8M | -$113,000 | $18.2M |
Source: SEC EDGAR filings · CIK 0001860657 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.